Using red cell phenotyping (RCP) and/or cytogenetics (CYT) we identified 19 patients with persisting mixed chimerism (MC) among 231 patients transplanted with partially T cell-depleted stem cell grafts from HLA-identical siblings. Persisting MC is defined as MC for more than 2 years in patients without any evidence of relapse. Median leukemia-free survival in these patients was 150 (range, 50-218) months. Diagnoses were ALL (n ‫؍‬ 10); AML (n ‫؍‬ 2); CML (n ‫؍‬ 2); NHL (n ‫؍‬ 2); MDS (n ‫؍‬ 1); MM (n ‫؍‬ 1) and SAA (n ‫؍‬ 1). 
Introduction
The major goal of allogeneic stem cell transplantation (SCT) for hematological malignancies is complete eradication of malignant cells together with the development of complete donor chimerism. With the use of increasingly sensitive techniques, mixed chimerism, defined as a mixture of both donorand recipient-derived hemopoietic cells, is frequently observed after allogeneic SCT. [1] [2] [3] The presence of mixed chimerism depends on several factors such as the intensity of the conditioning regimen, the use of T cell depletion and the number of stem cells infused. [4] [5] [6] [7] [8] [9] [10] [11] [12] Mixed chimerism with an increasing number of autologous cells may be a significant risk factor for subsequent relapse. 10, [13] [14] [15] The significance of persisting stable mixed chimerism is not clear as yet. Using more sensitive methods to evaluate chimerism after SCT, residual host cells may represent normal hematopoiesis without any evidence of recurrent disease. 10, 11, [16] [17] [18] We showed high incidences of mixed chimerism at 6 months and 1 year after SCT in patients who were transplanted with HLA-identical grafts that were partially depleted of lymphocytes by density gradient and counterflow centrifugation. Mixed chimerism at 6 months after SCT did not correlate with a higher incidence of relapse in further follow-up. However, mixed chimerism at 12 months after SCT indicated a higher relapse risk. 4, 19 Using red blood cell phenotyping and/or cytogenetic analysis we also identified a remarkable number of patients with persisting mixed chimerism for more than 2 years after SCT in a population of patients transplanted with HLA-identical T cell-depleted grafts. Our aim has been to determine prospectively the course and significance of MC in these patients. Additionally, we wished to evaluate chimerism in the various subsets of blood cells involved in this stable mixed chimerism. During follow-up, chimerism was monitored sequentially in these patients and patients were evaluated frequently for residual disease. In a substantial number of patients we were able to determine chimerism in the granulocytes and in various subsets of PBMCs such as monocytes, T cells, natural killer (NK) cells and B cells by a quantitative PCR-based technique for the analysis of microsatellite DNA regions.
Patients and methods

Patient characteristics
All patients who had a discriminating patient and/or donor marker and who underwent allogeneic T cell-depleted stem cell transplantation at the University Medical Centre St Radboud, Nijmegen, between 1983 and 1999 chimerism were sequentially monitored for chimerism. A cohort of 231 consecutively transplanted patients with a discriminating patient/donor marker survived for more than 2 years after SCT without any evidence of relapse from their original disease. These 231 consecutive patients were transplanted for acute myeloid leukaemia (AML) (n = 53), acute lymphoid leukaemia (ALL) (n = 41), chronic myeloid leukaemia in first chronic phase (CML-CP1) (n = 67), myelodysplastic syndrome (RA, RAEB and RAEB-t) (n = 25), intermediate and high grade B cell non-Hodgkin lymphoma (NHL) (n = 9), low grade NHL (n = 14), multiple myeloma (MM) (n = 12), chronic lymphoid leukaemia (CLL) (n = 3) and severe aplastic anaemia (SAA) (n = 7). Donors were HLA A, B, DRB and DQB-identical siblings. Chimerism was investigated using red blood cell phenotyping and cytogenetic analysis of bone marrow and/or blood. Using these techniques we identified 19 patients with persisting, relatively stable mixed chimerism. Persisting chimerism is defined as being mixed chimera for more than 2 years after SCT without any evidence of cytogenetic or hematological relapse. Patient characteristics of the 19 patients with persisting mixed chimerism are listed in Table 1 .
Conditioning regimen, GVHD prophylaxis and supportive care
The majority of patients (n = 165) were conditioned with an intensified conditioning regimen consisting of idarubicine 42 mg/m 2 by continuous intravenously (i.v.) infusion on days −12 and −11 followed by cyclophosphamide 60 mg/kg b.w. i.v. on each of 2 consecutive days (days −6 and −5). Fractionated total body irradiation (TBI) was given on days −2 and −1 to a total dose of 9 Gy. In 25 patients, TBI was intensified to 12 Gy midline dose and anthracyclines were omitted. Thirty-four patients were given cyclophosphamide 60 mg/kg b.w. i.v. on each of 2 consecutive days and TBI 9 Gy on days −2 and −1. The 10 patients transplanted for SAA were conditioned with a reduced intensity conditioning regimen consisting of 12 Gy total lymphoid irradiation given in 3 consecutive days followed by cyclophosphamide 50 mg/kg b.w. on each of 4 consecutive days. Donor marrow was partially depleted of lymphocytes by density gradient centrifugation followed by counterflow centrifugation as previously described. 20, 21 The median number of T cells in the marrow grafts was 0.7 (range, 0.4-1.9) × 10 6 CD3 + cells/kg b.w. All patients received prophylactic antibiotics according to institutional guidelines. Immunoprophylaxis after transplant consisted of cyclosporine A (CsA) 3 mg/kg/day by continuous i.v. infusion from days −1 to +14, followed by 2 mg/kg/day as a continuous i.v. infusion until day 21. Beyond day 21, CsA was administered orally at a dose of 6 mg/kg/day until 8 to 10 weeks after BMT. In the absence of GVHD, CsA was gradually tapered and discontinued at 12 weeks post-grafting. All patients were managed in single rooms with filtered air under positive pressure during their hospital stay.
Assessment of GVHD
Acute GVHD was classified from grades 0 to 4 according to the criteria described by Glucksberg et al. 22 Chronic GVHD was graded as none, limited or extensive. 23 
Chimerism analyzed by cytogenetic analysis and red blood cell phenotyping
Chimerism in all 240 patients was investigated prospectively by cytogenetic analysis of blood and bone marrow and/or by red blood cell phenotyping. Cytogenetic analysis of unstimulated bone marrow cells (myelo-monocytic and erythrocytic progenitor cells) and PHA-stimulated PBMCs (T cells) was performed routinely before BMT, 6 and 12 months after BMT and annually thereafter as described previously. 24, 25 The median number of bone marrow metaphases analyzed was 30 (range, and the median number of metaphases of lymphocytes was 32 (range, 7-32), allowing a sensitivity level of 10-12%. 26 When the recipient and donor were of different sex, heterosome determination of 400 interphases (fluorescent in situ hybridization: FISH) allowed additional differentiation between donor and host cells, resulting in a sensitivity of 1% for the demonstration of a minor cell population. Red blood cell phenotyping was performed using a flow cytometric and/or fluorescent microscopic microsphere method as described previously. [27] [28] [29] The sensitivity level is 0.1-0.3% for the flow cytometric method and 0.01% for the fluorescent microscopic technique. At the level of 0% patient or donor red cells, the flow cytometric results were always controlled by the fluorescent microscopic method in order to increase the sensitivity to a level of 0.01%. The time schedule for analysis was 1, 2, 3, 6 and 12 months after BMT and annually thereafter.
Chimerism in granulocytes and PBMCs subsets using PCR-STR analysis
In nine out of 19 patients with persisting mixed chimerism as found with RCP and/or cytogenetics, chimerism was analyzed in granulocytes and PBMC subsets by amplification of short tandem repeats (STR) markers. Immunophenotypical markers used to discriminate between the different subsets were
+ (granulocytes) and CD3 − /CD56 + (NK cells). Analysis of these subsets was performed at a median of 8 years (range, 3-12) after SCT. A panel of four microsatellite markers (CSF1PO, TPOX, THO1 and vWA; Promega GenePrint Fluorescent STR Systems, Madison, WI, USA) in one multiplex PCR was used in the initial screening process to identify at least one polymorphic marker. Samples were analyzed using only the informative primer pair. Briefly, genomic DNA was isolated from whole EDTA blood of the donor and recipient (pretransplant) by salt extraction. 30 A serial dilution was prepared by mixing donor DNA with recipient DNA. The sorted subsets were lysed. 31 The samples were amplified using the manufacturer's directions with 100 ng DNA or 14 000 lysed cells as template.
Granulocytes were separated from mononuclear cells by Ficoll-Hypaque density gradient centrifugation. Mononuclear cells were further purified using a magnetic cell separation technique (MiniMacs; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. After direct staining with anti-CD4, anti-CD8, anti-CD14 and anti-CD19 Microbeads (Miltenyi Biotec), these cells were magnetically isolated on MiniMacs columns. After washing twice with staining buffer, followed by elution with staining buffer in the absence of any magnetic field, subsets with a purity of 93-97% were obtained. Granulocytes were directly isolated after lysing the red blood cells and after incubating with anti-CD45-FITC and anti-CD15-PE using flow cytometric sorting (CoulterElite, Miami, FL, USA). NK cells were directly sorted after incubating with anti-CD56-PE and anti-CD3-FITC, respectively. All magnetic sorted subsets were re-incubated with fluorescent antibodies specific for each cell population and were resorted on the flow cytometer to obtain a purity of more than 98% in each subset.
PCR products were detected and quantified by capillary electrophoresis (Beckman P/ace system 5000 with LIF detector; Beckman, Fullerton, CA, USA) with a 37 cm × 50 (m capillary (Applied Biosystems, Norwalk, CT, USA) using Performance Optimised Polymer 4 (Applied Biosystems). 32 PCR products were diluted 50× in dH 2 O, denatured for 5 min and stored on ice for 5 min before loading. Samples were injected Leukemia electrokinetically for 7 s 10 kV and separated at 10 kV at 55°C in 2× genetic analyzer buffer (Applied Biosystems). Quantification was done by comparing the samples with the serial dilution.
Calibration of product (Y) was done with a series of serial diluted samples with (donor concentration C, 0 р C р 1). The data were fitted with Y Ϸ C/(1-C) (UlraFit; Biosoft, Cambridge, UK). Quantification was performed by root finding in the fitted curve.
The sensitivity of this technique varies between 0.5 to 1% and is also dependent on the amount of DNA tested and the specific discriminating STR locus.
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Results
Sequential monitoring of patient-and donor-derived blood cells using red blood cell phenotyping and/or cytogenetic analysis in 231 consecutive patients resulted in the identification of 19 patients with persisting mixed chimerism ( Table  1) .
Only eight of 165 (5%) patients conditioned with the addition of anthracyclines developed persisting mixed chimerism. In contrast, 11 of 66 (17%) patients conditioned without the addition of anthracyclines became persisting mixed chimera (P = 0.0031, chi-square). Persisting mixed chimerism was found in 12 out of 67 patients (18%) transplanted for lymphoid malignancies compared to seven out of 164 patients (4%) transplanted for non-lymphoid diseases (P = 0.0006, chisquare). These two groups did not differ from each other in the conditioning regimens used, T cell dose in the stem cell grafts and graft-versus-host characteristics.
The median number of CD3 + T cells in the stem cell grafts did not differ between the patients who did develop persisting mixed chimerism after SCT and those who did not. The median T cell dosages were 0.7 (range, 0.3-1.4) × 10 6 /kg body weight and 0.7 (range, 0.4-1.9) × 10 6 /kg body weight, respectively.
Three out of 19 patients (16%) with persisting mixed chimerism suffered from acute GVHD у grade 2 and none had extensive chronic GVHD. Twelve out of 212 (6%) patients without persisting mixed chimerism had acute GVHD у grade 2 and 23 of 212 patients (11%) had extensive chronic GVHD (P = 0.09 and P = 0.13, respectively, chi-square).
Follow-up of 19 patients by red blood cell phenotyping and cytogenetics
In four out of 19 patients (UPN 15, 40, 60 and 388) early after SCT, a relatively high and stable number of autologous cells was detected with recipient cells ranging from 50 to 100% at end of follow-up (Figure 1) . Figure 1 depicts the percentages of autologous cells detected by RCP and cytogenetic analysis. If cytogenetic analysis resulted in different percentages of autologous cells detected simultaneously in unstimulated bone marrow cells (myelo-monocytic and erythrocytic progenitor cells) and PHA stimulated PBMC (T cells), the highest percentage is given in Figure 1 . In UPN 388 transplanted for AML-M5 1 year after SCT, 99% of the blood and marrow cells were of recipient origin and after 3 years the cytogenetic marker of the original disease (Xp-) also reappeared. Peripheral blood counts remained normal for 4 years and the cytogenetic marker did not disappear after repeated donor leukocyte infusions. After 4 years this patient developed a One patient (UPN 31) developed 52% autologous cells over a period of 5 years. From this moment onwards, annual bone marrow evaluation stopped but at 12 years after BMT 19% of the bone marrow cells still turned out to be of autologous origin. This patient lacked a red blood cell marker.
Seven out of the nine patients mentioned above had both a discriminating red blood cell and cytogenetic marker ( Figure  1) . In all these patients the relatively high number of recipient red blood cells was simultaneously represented by a relatively high number of recipient bone marrow cells (Figure 1 ). In one of these nine patients (UPN 268) the increasing number of recipient cells represented a pending relapse of CML. The BCR/ABL fusion protein increased in blood and bone marrow and cytogenetic relapse was detected 4 years after SCT. The patient subsequently received an infusion of 0. (6-43%) . UPN 161 always showed autologous red cells but autologous cells were never found using cytogenetic analysis. In the majority of the patients with Ͻ1% autologous red cells, these cells could not be quantified using cytogenetics as a consequence of the difference in sensitivity levels between these tests. UPN 31 lacked a discriminating red cell marker but cytogenetically the percentage of autologous cells varied between 3% and 52% with a most recently observed percentage of 19%.
Chimerism in granulocytes and PBMC subsets analyzed by PCR-STR
The percentages of recipient cells detected by PCR-STR technique in granulocytes and PBMC subsets are listed in Table 2 . The percentage of CD3 − /CD56 + NK cells did not correlate with that of any of the other subpopulations of blood nor with that of bone marrow cells.
As expected, no correlation was found between the recipient B lymphoid and T lymphoid subsets with the exception of the two patients who were complete donor chimera at the time of the PCR-STR analysis (UPN 108, UPN 161) .
Within each individual patient the percentages of donor and recipient cells were very different between the subsets investigated ( 
Discussion
Since the introduction of more sensitive techniques to investigate chimerism after SCT, the persistence or reappearance of autologous cells has been observed more frequently, especially in patients who received T cell-depleted grafts. 26, 36, 37 Mixed chimerism after allogeneic SCT may represent very different modalities and is influenced by a number of interacting parameters like the underlying malignancy, the conditioning regimens, the number of T cells in the graft and graft-versus-host disease after SCT. Also, the techniques used to detect the chimerism and their sensitivity have influenced its significance after SCT. [38] [39] [40] Residual autologous hemopoiesis may represent residual normal cells belonging to one or more specific subsets that survived the conditioning regimen and that are tolerated by the transplanted donor immune system. However, these cells may also originate from the malignant clone and represent residual disease controlled by an active donor-derived immune system. Chimerism after SCT is a dynamic process and its significance can only be investigated by sequential monitoring of the co-existence of donor and patient cells. The long-term clinical significance of mixed chimerism after SCT remains a matter of discussion. Some studies found high relapse rates in patients with mixed chimerism after T cell-depleted SCT. [41] [42] [43] [44] [45] Other studies could not demonstrate this correlation. 7, 15, 46 It may be very important to distinguish between patients with a slowly decreasing number of autologous cells, patients with an increasing number of autologous cells, and patients who are complete donor chimera and subsequently become mixed chimera again. The different subsets of hemopoietic cells involved in the mixed chimerism may also influence outcome in further follow-up of these patients. 40 Several studies using sequential analysis of post-transplant chimerism showed that patients with increasing mixed chimerism had the highest risk of relapse. 45, 47, 48 Using red blood cell phenotyping and/or cytogenetic analysis we showed that mixed chimerism at 6 months after partially T cell-depleted SCT was not correlated with relapse. However, if we extended our observations, the presence of mixed chimerism at 12 months after transplantation was correlated with an increased probability of relapse. 4 The differences in these relapse rates were explained by a relatively high number of patients with an decreasing number of recipient cells who were still mixed chimera at 6 months after SCT and who had changed to complete donor chimeras at 12 months after BMT. In a relatively high number of patients this would have been transient T cell chimerism as demonstrated by decreasing numbers of autologous cells in the peripheral blood as shown by cytogenetic analysis. We also demonstrated that the reappearance of autologous red blood cells in CML patients with complete donor chimerism was a very sensitive marker for a pending relapse. 49 In this study, we describe 19 patients who were sequentially monitored for chimerism during a long (median 150 months) period after SCT and who were persisting mixed chimera for more than 2 years after SCT without any evidence of cytogenetic or hematological relapse of their original disease. These patients were analyzed sequentially using red blood cell phenotyping and cytogenetics to study the dynamics of the chimerism. The incidence and severity of acute and chronic GVHD was low although the number of CD3 + cells in the stem cell grafts did not differ between these 19 patients and the remaining 219 patients who developed complete donor chimerism after transplantation. During further follow-up only two out of 19 patients with persisting mixed chimerism relapsed from the original disease (AML, CML). The findings on these serially collected samples from patients in long-term continuous complete remission show the kinetics of residual recipient cells, with almost no apparent correlation with posttransplant events. An important factor that influenced chimerism after SCT was the introduction of anthracyclines to the conditioning regimen. Mixed chimerism occurred significantly more frequently in the patients conditioned without anthracyclines. An earlier multivariate analysis performed on 181 standard risk patients previously underlined the importance of the addition of anthracyclines to the conditioning regimen in relation to the development of acute GVHD, mixed chimerism and relapse. 4 Another remarkable observation is the overrepresentation of patients with lymphoid malignancies in the group of patients with persisting mixed chimerism. Compared to the patients with non-lymphoid malignancies, these patients did not differ in conditioning regimens, the number of CD3
+ cells present in the stem cell grafts and the incidence and severity of GVHD. This observation may be explained by the presence of re-emerging autologous lymphocytes not belonging to the malignant clone that escaped from the primary GVL effect. It is known that patients with ALL may escape the GVL effect more easily compared to patients suffering from myeloid or mature lymphoid malignancies like lowgrade NHL, multiple myeloma or CLL. 50, 51 This phenomenon is also correlated with low response rates after therapeutic donor lymphocyte infusions in patients with relapsed ALL. 52 The reappearance of recipient cells may weaken the GVL effect of donor effector cells, possibly as a result of the induction of immune host and/or donor tolerance or as a result of indirect mechanisms such as negative signalling. 39 In patients with complete donor chimerism after SCT, alterations in expression of surface co-stimulatory molecules might lead to anergy or to a lack of allo-reactivity in donor lymphocytes grown in a donor environment providing the opportunity for benign or malignant autologous cells to expand. 50, 53 Persisting mixed chimerism without relapse as described in this study may be explained by complete eradication of the malignant clone with selective survival of residual normal autologous hemopoietic stem cells after transplantation. In seven patients we observed a very slowly transient mixed chimerism with a low number of recipient cells that disappeared gradually after a median of 7 years post SCT. In these patients a small number of autologous cells must have survived the conditioning regimen and must also have been able to escape the graft-versus-leukemia effect. Finally, in these patients the immunological balance was tipped towards complete donor hemopoiesis with no detectable autologous cells using the techniques described, which means that either residual host hemopoiesis represents a transient event or it persists longer but below the detection level of the method used to evaluate chimerism. 54 Another explanation for the survival of autologous blood cells after SCT may have been the presence of cytotoxic T lymphocytes in the stem cell graft directed towards leukemiaassociated minor histocompatibility antigens. 55 This specific cytotoxicity may result in reactivity only directed at the malignant lymphoid cells and not directed towards residual host hemopoietic cells lacking the leukemia-specific antigen and consequently creating an opportunity for mixed chimerism without relapse of the original disease.
To obtain additional information about the specific subsets of blood cells involved in the mixed chimerism, STR analysis on highly purified PBMC subsets and granulocytes was performed in nine patients. In this analysis, red blood cell phenotyping correlated well with cytogenetic analysis of the bone marrow. We also found concordant data comparing cytogenetics of the bone marrow with myelo/monocytic subsets analyzed using PCR-STR. The PCR-STR analysis also established the difference between mixed chimerism observed using cytogenetic analysis of the blood and cytogenetics of the bone marrow, respectively. Another observation was the good correlation between PHA-stimulated T cells in the peripheral blood and the mean number of recipient T cells represented as the per- + (NK cells) subsets in a patient transplanted for T-ALL to mixed chimerism in all investigated subsets in four patients transplanted for B lymphoid malignancies (ALL, n = 3 and high-grade non-Hodgkin's lymphoma n = 1). Patients had a long-lasting event-free survival without any evidence of residual disease.
Chimerism studies in purified subpopulations during the first year after SCT resulted in mixed T lymphoid chimerism represented by host-type cells in the T cell lineage that only gradually disappeared in the first year after SCT. 47, 56 This type of chimerism could only be demonstrated in the peripheral blood and was not found in the bone marrow, however the number of evaluable patients was low. In the present study, subpopulations were analyzed late after SCT (median of 8 years) and only peripheral blood samples were analyzed for chimerism in subsets. Chimerism restricted to the T cell lineage only could not be demonstrated. Using cytogenetics we did not identify patients with autologous cells restricted to the peripheral blood only (T cells) and complete donor chimerism in the bone marrow which is concordant with the PCR-STR results in PBMC subsets. Patient UPN 268 showed a chimerism pattern specific for relapsing CML with autologous cells detectable in the red blood cells, granulocytes and monocytes and complete donor T cell chimerism. The low number of patient red blood cells in UPN 108 and UPN 161 may also represent microchimerism in all other subsets, however, this could not be proved because of the lower sensitivity level of the STR-PCR technique.
In conclusion, this is the first study in which patients are described with long-term stable mixed chimerism who have been followed for many years. We show the dynamics of this chimerism resulting in a very slowly transient chimerism, almost autologous repopulation and relatively stable mixed chimerism in different subgroups, respectively. We also demonstrate a great individual difference in hemopoietic cells involved in this chimerism. Mixed chimerism did not correlate with relapse in further follow-up despite the fact that the majority of these patients were conditioned with less intensive conditioning regimens and they also had little GVHD. There was a relationship between the type of leukemia and the incidence of persisting mixed chimerism although this difference disappeared after intensifying the conditioning regimen by the introduction of anthracyclines. We think that these observations may contribute to the interpretation of chimerism especially in the context of mixed chimerism after reduced intensity conditioning regimens in allogeneic SCT. The impact of anthracyclines in the conditioning regimens on the outcome and chimerism after SCT is currently under investigation in a randomized prospective multicenter trial.
